[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases. HEPATOLOGY, 2018,67:328-357.
[2] McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol, 2015,62:1148-1155. .
[3] Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in japanese patients tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care, 2010,33:284-286. .
[4] Chan WK, Ida NH, Cheah PL, et al. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow up study. J Dig Dis, 2014,15:545-552. .
[5] Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018,67:123–133.
[6] Thuluvath PJ, Kantsevoy S, Thuluvath AJ, et al. cryptogenic cirrhosis different from NASH cirrhosis? J Hepatol, 2018,68:519-525.
[7] Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999,30:1356-1362.
[8] Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology, 2012,56:943-951. .
[9] Yang JD, Abdelmalek MF, Pang H, et al. Gender and meno-pause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology, 2014,59:1406-1414. .
[10] Koo BK, Joo SK, Kim D, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2018,33:1277-1285. .
[11] Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun, 2014, 5:4309. .
[12] Boursier J, Mueller O, Barret M, et al. The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology, 2016,63:764-775. .
[13] Lee YH, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). Hepatology, 2016,63:776-786.
[14] Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 2013,145:782-789.e4.
[15] Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease. Gastro-enterology, 2018,155:443-457.e17.
[16] Angulo P, Kleiner DE, Dam-Larsen S,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015,149:389-397.
[17] McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 2010,59:1265-1269.
[18] Daniels SJ, Leeming DJ, Eslam M, et al. Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with non-alcoholic fatty liver disease. J Hepatol, 2017,66, S671-S671.
[19] Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol, 2008,7:350-357.
[20] Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007,45:846-854.
[21] Shah AG, Lydecker A, Murray K, et al.Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2009,7:1104-1112.
[22] Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut, 2008,57:1441-1447.
[23] Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology, 2016,150:626-637.
[24] Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. HEPATOLOGY, 2010,51:454-462.
[25] Bedossa P, Patel K, et al. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology, 2016,150:1811-1822.
[26] Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the sportDiet study. HEPATOLOGY, 2017,65:1293-1305.
[27] Rebibo L, Gerin O, Verhaeghe P, et al. Laparoscopic sleeve gastrectomy in patients with NASH-related cirrhosis: A case-matched study. Surg Obes Relat Dis, 2014,10:405-410. .
[28] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 2015,149:367.
[29] Barritt AS, Dellon ES, Kozlowski T, et al. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol, 2011, 45: 372-378.
[30] Afzali A, Berry K, Ioannou GN, et al. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl, 2012, 18: 29-37.
[31] Singal AK, Salameh H, Kuo YF, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation, 2013, 95: 755-760.
[32] Malik SM, deVera ME, Fontes P, et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant, 2009, 9: 782-793.
[33] Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in US veterans is associated with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2016,14:124-131.
[34] Petta S, Sebastiani G, Bugianesi E, et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. Journal of Hepatology, 2018,69:878-885. |
